SHARDACROPNSE24 January 2023

Sharda Cropchem Limited has informed the Exchange about Investor Presentation

Sharda Cropchem Limited

24th January, 2023

To,

National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

BSE Limited Phiroze Jeejeebhoi Tower, Dalal Street, Mumbai – 400 001

Trading Symbol: SHARDACROP

Scrip Code: 538666

Subject: Investors / Analyst’s Presentation for the quarter and nine months ended 31st December, 2022:

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing herewith the presentation to be made to the Investors/Analysts on the Financial Results of the Company for the quarter and nine months ended 31st December, 2022.

The presentation is also being uploaded on the website of the Company www.shardacropchem.com the Listing Regulations.

in accordance with Regulation 46 of

We request you to take the same on record.

Yours Sincerely,

__________________ Jetkin Gudhka Company Secretary & Compliance Officer

Encl.: As above

Investor Presentation January 2023

Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sharda Cropchem Limited (the “Company”), have been prepared solely for

information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection

with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed

information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty,

express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This

Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this

Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively

forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions

that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets,

the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion,

technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as

other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation.

The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties

included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

About Sharda Cropchem Limited

“We are a fast-growing global agrochemicals company with a peer position in the generic crop protection chemicals industry. Our vast and growing library of dossiers and IPRs provide us solid foundations for growth in the global marketplace, especially in Advanced Markets such as Europe, North America and Latin America. It equips us with the ability to operate in a diversified range of formulations and generic active ingredients space globally”

Agrochemical Focused Company

Intellectual Property (IP) driven company engaged in marketing and distribution of wide range formulations and generic active ingredients

Asset Light Business Model

Efficiently channelizing time and resources for strengthening core competency of identifying generic molecules and registration opportunities which offer scalable growth with limited capital requirements

Large Pipeline of Registrations*

Procured 2,776 registrations. Additionally, it has filed 1,131 applications for registrations globally pending at different stages

Diversified Sourcing Arrangements

Enduring relationship with multiple manufacturers and formulators enables to source and supply formulations or generic active ingredients at competitive prices

Consistently Increasing Global Presence

With diversified range of product portfolio, Company has grown by expanding business operations in 80+ countries, across Europe, NAFTA, Latin America and ROW

Widespread Distribution Network

Presence in the entire agrochemical value chain with 500 third party distributors and 400+ sales force serving the Company’s esteemed clientele in 80+ countries

Company’s apt domain knowledge and experience gives substantial competitive advantage for expanding business in existing markets and new geographies

*As on 31st December 2022

Asset Light Business Model

Overall Agrochemical Value Chain

Sharda’s Operating Area

√

Basic & Applied Research

Identification

Registration

Active Ingredient Manufacturing

Formulation & Packaging

Marketing & Distribution

SHARDA CROPCHEM’s ASSET LIGHT BUSINESS MODEL

Focus on identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulations through third-party distributors and/or own sales force

Manufacturing of AIs and formulations is outsourced

Highly flexible operating model resulting in • Overall cost competitiveness • Efficient management of fluctuating market

demand across various geographies

• Offering wide range of formulations and AIs

Acts as a key differentiator from an innovator company, allowing the Company to save its capital, time and resources on R&D

Increasing Global Presence having a Widespread Distribution

Presence 80+ countries

across Europe, NAFTA, LATAM & RoW

Sales Force 400+

Distributors 500+

CAPEX incurred in 9MFY23* Rs. 300 Cr.

Over the years, we’ve built a strong brand franchise within our global markets; we are benefiting through the economies of scale in our portfolio and leveraging value of our supply chain to deliver value to our customers across geographies

Company has gained a great deal from globalization, including new customers and diverse geocentric revenue streams. Over the years, we have mastered flexibility and adopted innovative ways to grow our business overseas

In addition to newer markets, the wide global presence has allowed us to find new, specialised sales and local marketing talent.

Successfully adopted a factory-to- farmer approach to become a one- stop solution provider to our global customers

Strengthening and widening the sales force in Europe, USA, Canada, Mexico, Colombia, South Africa, India, and rest of the world, in addition to third party distributors with a goal to enhance its presence in the agrochemical value chain

It enables the Company to penetrate its formulations and generic active ingredients in various countries backed by the third-party distributors and presence of its own sales force

* Plus related revenue expenditure on registrations

The Sharda Advantage

THE SHARDA ADVANTAGE

Global Reach

Wide Product Range

Healthy relationships with suppliers

Quality with Affordability

Faster Sales Service

One Stop Solution Provider for Crop Care Products

Way Forward

Forward Integration - Build Sales Force

Expand & Strengthen Distribution Presence

➢ Leverage market presence and execution capabilities

➢ Expand geographical reach using existing library of

➢ Adopt the factory to farmer approach and be a one stop

solution provider

➢ Strategy on ground in different regions of NAFTA, Europe, LATAM and other key markets in ROW

dossiers

➢ Two-fold strategy of further penetrating existing markets

and entering new markets

Continual Investment in Product Registrations

Focus on Operational Efficiencies

➢ Continue to identify generic molecules going off patent

➢ Accelerated focus on revenue generating investments

➢ Investing in preparing dossiers and seeking registrations

➢ Margin improvements

in own name

➢ Better cost management and eliminate NVAs

Industry Outlook and Growth Drivers

Global crop protection chemicals market value (In Billion USD) – CAGR of 3.5%

59.7

8.1

42.0

62.8

77.0

43.7

53.0

5.3

2020

3.9

0.5

8.4

5.9

4.3

0.6

2025e

10.2

7.7

5.4

0.8

2030e

Herbicide

Fungicide

Insecticide

Nematicide

Molluscicide

INDUSTRY DRIVERS

A growing population: the global population is set to increase by 1.2 billion by 2030 and 2 billion by 2050, while the middle class will more than double to 4.9 billion by 2030

A growing middle class fuels demand for increased food and protein production, which in turn drives demand for grain to support growth

Fewer arable acres per capita means that products need to continue to maximise farmer yields; arable land is expected to decrease from half an acre per person today to less than one- third of an acre per person by 2050

Primary Research, Secondary Research, Magna Information Centre

Experienced Management

Mr. Ramprakash V. Bubna Chairman & Managing Director

Mr. Ashish Bubna Whole Time Director

Mr. Manish Bubna Whole Time Director

Mr. Ashok Vashisht Chief Financial Officer

•

Holds a Bachelor’s Degree of Technology in Chemical Engineering from IIT, Bombay

He has over 53 years of experience in chemicals, agrochemicals and related businesses

He is responsible for the Company’s overall business operations and strategy

•

Holds a Bachelor’s Degree in Commerce from the University of Mumbai

Over 30 years of experience in marketing of chemicals, agrochemicals and related businesses.

Instrumental in strategizing early investment in product registrations and building the library of product dossiers.

Responsible for marketing, procurement, registrations and logistics functions of the agrochemical business.

•

Holds a Bachelor’s Degree in Chemical Engineering from the Department of Chemical Technology, Bombay University.

Over 28 years of experience in chemicals, agrochemicals and related businesses

Spearheaded the Company’s foray into the conveyor belt and general chemicals business

Also oversees the information technology, logistics and documentation functions of the Company

•

He is Fellow member of Chartered Institute of Management Accountants UK & accredited CGMA, Fellow member of CPA Australia, Fellow member of The Institute of Cost Accountants of India and Associate member of The ICSI. He has also done DipIFR from ACCA UK and qualified Independent Director from IICA

25+ years of rich professional corporate experience in global and Indian MNCs in the field of Strategy, M&A, Financial Management, Direct & Indirect Taxation, Strategic Cost Management, Project Management, Statutory Audits & Internal Audits, Governance & Risk Management

Q3 FY23 Financial Highlights

Q3 FY23: Segment Wise Highlights

Agrochemical Segment

Non Agrochemical Segment

TOTAL REVENUES

82%

723

83%

842

18%

157

17%

175

% of Revenue

100%

880

1,017

Cr.

Q3FY22

Q3FY23

Q3FY22

Q3FY23

Q3FY22

Q3FY23

+16%

+12%

+16%

On Consolidated Basis

Q3 FY23: Product Wise Highlights (Agrochemical Segment)

Herbicides

Insecticides

Fungicides

Cr.

TOTAL REVENUES (Agrochemical Segment)

51%

60%

23%

12%

26%

28%

% of Revenue

100%

505

166

240

366

191

842

723

Q3FY22

Q3FY23

Q3FY22

Q3FY23

Q3FY22

Q3FY23

Q3FY22

Q3FY23

+38%

- 42%

+26%

16%

On Consolidated Basis

Q3 FY23: Region Wise Breakup (Agrochemical Segment)

Europe

NAFTA Region

42%

302

+9%

39%

330

43%

312

+27%

47%

394

Q3FY22

Q3FY23

Q3FY22

Q3FY23

LATAM Region

-5%

RoW

+17%

Q3FY22

Q3FY23

Q3FY22

Q3FY23

% of Revenue

Cr.

TOTAL REVENUES (Agrochemical Segment)

842

723

Q3FY22

Q3FY23

+16%

On Consolidated Basis

Q3 FY23: Region Wise Breakup (Non Agrochemical Segment)

Europe

NAFTA Region

38%

-57%

14%

44%

+67%

66%

115

Q3FY22

Q3FY23

Q3FY22

Q3FY23

LATAM Region

+102%

RoW

+9%

15%

Q3FY22

Q3FY23

Q3FY22

Q3FY23

% of Revenue

Cr.

TOTAL REVENUES (Non - Agrochemical Segment)

157

175

Q3FY22

Q3FY23

+12%

On Consolidated Basis

Q3 FY23: Financial Highlights

Revenues & GP Margin

EBITDA & EBITDA Margin*

Cr.

33.9%

880

30.5%

1,017

Revenue growth led by better product mix, price realization and volume growth. Gross Margins have been impacted by weakening of €/$ leading to increased input cost vs Q3FY23 ,but improved vs Q2FY23.

+16%

22.8%

19.3%

201

197

Q3FY22

Q3FY23

Q3FY22

Q3FY23

EBITDA and Margin impacted due to lower GP Margins driven by weakening of €/$ leading to increased input cost and general inflation.

- 2%

Profit After Tax & PAT Margin

Profit After Tax & PAT Margin (Excluding Forex Impact)

11.6%

10.7%

102

108

PAT growth was led by volume growth, better price mix and fav impact of forex gain during the quarter ending Q3 FY23.

+6%

12.2%

108

9.4%

- 11%

De-growth mainly due to lower GP Margins driven by weakening of €/$ leading to increased input cost

Q3FY22

Q3FY23

Q3FY22

Q3FY23

* EBITDA is excluding IA & IAUD write-off (Rs. 2.2 cr. in Q3 FY23; Rs. 7.0 cr. in Q3 FY22

On Consolidated Basis

Impact of weakened Euro to the Dollar in the last nine months

USD / Euro Price Chart

1.11

1.1500

1.1000

1.0500

1.0000

0.9500

Unprecedented depreciation of Euro to the USD - 12%

0.98

01-04-2022

01-05-2022

31-05-2022

30-06-2022

30-07-2022

29-08-2022

28-09-2022

28-10-2022

27-11-2022

27-12-2022

Euro Dollar Exchange Rate

Major currencies have depreciated to the USD in the first six months of the financial year due to the ongoing war between Russia & Ukraine. In Q3FY23, we have seen a rebound of these currencies.

Over 44% of 9M FY23 Sales from Agrochemical business have been to the Europe whereas majority of the Company’s Raw Material is imported from China and payments are done in US Dollar

This has impacted the Company’s Gross Margin and overall profitability as the Euro had considerably depreciated against the dollar

MEASURES TAKEN BY COMPANY

•

Increased sales focus on NAFTA region

• Sourcing in Euro currency

• Optimal Hedging of currencies

• Seeking Price increase to minimize this forex impact

9M FY23 Financial Highlights

9M FY23 Segment Wise Highlights

Agrochemical Segment

Non Agrochemical Segment

TOTAL REVENUES

82%

1,760

79%

2,032

18%

385

21%

531

% of Revenue

100%

2,563

2,145

Cr.

9MFY22

9MFY23

9MFY22

9MFY23

9MFY22

9MFY23

+15%

+38%

+19%

On Consolidated Basis

9M FY23: Product Wise Highlights (Agrochemical Segment)

Herbicides

Insecticides

Fungicides

Cr.

TOTAL REVENUES (Agrochemical Segment)

50%

58%

26%

16%

24%

26%

% of Revenue

100%

1,185

461

520

882

327

417

2,032

1,760

9MFY22

9MFY23

9MFY22

9MFY23

9MFY22

9MFY23

9MFY22

9MFY23

+34%

-29%

+25%

+15%

On Consolidated Basis

9M FY23: Region Wise Breakup (Agrochemical Segment)

Europe

NAFTA Region

44%

768

+15%

43%

881

38%

666

+23%

40%

816

9MFY22

9MFY23

9MFY22

9MFY23

LATAM Region

11%

205

-6%

10%

193

RoW

+18%

142

121

9MFY22

9MFY23

9MFY22

9MFY23

% of Revenue

Cr.

TOTAL REVENUES (Agrochemical Segment)

2,032

1,760

9MFY22

9MFY23

+15%

On Consolidated Basis

9M FY23: Region Wise Breakup (Non Agrochemical Segment)

Europe

NAFTA Region

33%

125

-7%

22%

117

+76%

59%

313

46%

178

9MFY22

9MFY23

9MFY22

9MFY23

LATAM Region

+86%

RoW

+8%

13%

17%

9MFY22

9MFY23

9MFY22

9MFY23

% of Revenue

Cr.

TOTAL REVENUES (Non - Agrochemical Segment)

531

385

9MFY22

9MFY23

+38%

On Consolidated Basis

9M FY23: Financial Highlights

Revenues & GP Margin

EBITDA & EBITDA Margin*

Cr.

30.8%

2,145

28.0%

2,563

Revenue growth led by better product mix and price realization.

+19%

Gross Margins have been impacted by weakening of €/$ leading to increased input cost.

19.2%

16.2%

411

414

9MFY22

9MFY23

9MFY22

9MFY23

EBITDA and EBIDTA Margins were impacted due to lower GP Margins driven by weakening of €/$ leading to increased input cost, general inflation and strengthening of global workforce to support future growth.

+1%

Profit After Tax & PAT Margin

Profit After Tax & PAT Margin (Excluding Forex Impact)

8.0%

172

5.6%

143

- 17%

PAT was mainly impacted by increased forex losses of Rs. Rs. 69 crores in 9M FY23 and lower gross margins

8.4%

180

8.3%

213

+18%

Mainly due to revenue growth, better product mix and operational efficiencies.

9MFY22

9MFY23

9MFY22

9MFY23

* Excluding Other expenses of Rs 13.25 Crs. towards loss on fair valuation of investments during nine months ended December 31, 2022 as against gain of Rs.4.84 Crs. for corresponding nine months ended December 31, 2021 which has been included under Other Income

* EBITDA is excluding IA & IAUD write-off (Rs. 2.2 cr. in Q3 FY23; Rs. 7.0 cr. in Q3 FY22 ; Rs. 6.5 cr. in 9M FY23; Rs. 11.4 cr. in 9M FY22

On Consolidated Basis

Strong Balance Sheet

Working Capital (in Days)

72 days

86 days

104

102

103

119

RoCE

+550 bps

RoE

+470 bps

20.2%

25.7%

15.2%

19.8%

Mar-21

Mar-22

Mar-21

Mar-22

Total Equity

Total Debt

Cash & Cash Equivalents

Dec-21

Dec-22

Inventory Days

Recievable Days

Creditor Days

Rs. 2,049 crores

Rs. 3 crores

Rs. 303 crores

Rs. 1,912 crores as on Mar’22

Rs. 38 crores as on Mar’22

Rs. 300 crores as on Mar’22

ROE: PAT/Avg. Equity, ROCE: EBIT/Avg. Capital Employed [(Capital Employed = Equity + Total Debt)]

On Consolidated Basis

Annexure

Q3 & 9M FY23 Financial Highlights

Particulars

Revenue from Operations

Q3 FY23

1,017.3

COGS

Gross Profit

Gross Margin %

Employee Expenses

Other Expenses

EBITDA*

EBITDA Margin %

Forex (Gain)/Loss

Depreciation

Other Income

EBIT

EBIT Margin %

Finance Cost

PBT

Tax Expense

PAT

PAT Margin %

Earnings Per Share (EPS) In Rs.

PAT (Excluding Forex Impact)

PAT Margin % (Excluding Forex Impact)

707.3

310.0

30.5%

12.6

102.8

196.7

19.3%

-12.4

65.3

2.7

144.3

14.2%

0.9

143.4

35.0

108.4

10.7%

12.01

96.0

9.4%

Q3 FY22

879.8

581.4

298.4

33.9%

10.8

93.6

200.9

22.8%

5.6

59.0

6.9

136.2

15.5%

0.4

135.8

33.6

102.2

11.6%

11.33

107.7

12.2%

Y-o-Y

16%

(-2%)

(-11%)

9M FY23

2,563.3

1,846.9

9M FY22

2,145.3

1,484.5

Cr.

Y-o-Y

19%

716.5

28.0%

29.6

292.5

414.1

16.2%

69.5

180.5

33.2

177.6

6.9%

2.0

175.6

32.5

143.1

5.6%

15.86

212.6

8.3%

660.8

30.8%

31.4

229.4

411.3

19.2%

7.2

173.6

26.2

245.3

11.4%

1.5

243.8

71.5

172.3

8.0%

19.10

179.5

8.4%

(-17%)

18%

* EBITDA is excluding IA & IAUD write-off (Rs. 2.2 cr. in Q3 FY23; Rs. 7.0 cr. in Q3 FY22 ; Rs. 6.5 cr. in 9M FY23; Rs. 11.4 cr. in 9M FY22)

On Consolidated Basis

Balance Sheet - Consolidated

EQUITY & LIABILITIES Equity Equity share capital Other equity Equity attributable to equity holders of the Company Non-controlling interests Total Equity Non-current liabilities Financial liabilities Lease liabilities Trade payables

total outstanding dues of micro enterprises and small enterprises other than micro enterprises and small enterprises

Other financial liabilities Provisions Deferred tax liabilities (net) Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables

total outstanding dues of micro enterprises and small enterprises other than micro enterprises and small enterprises

Other financial liabilities Other current liabilities Provisions Income Tax Provisions Total current liabilities Total Equity & Liabilities

Dec-22

Mar-22

ASSETS

Dec-22

Mar-22

Cr.

90.2 1,958.1 2,048.3 0.3 2,048.6

0.7

2.5 142.4 145.5

2.6 4.1

4.4 1,374.1 415.4 55.0 103.6 2.5 1,961.8 4,155.9

90.2 1,822.2 1,912.5 0.3 1,912.8

3.5

0.0 2.4 1.6 2.3 128.9 138.6

38.0 5.1

8.8 1,168.8 324.8 55.4 86.7 4.2 1,691.8 3,743.1

Non-current assets

Property, plant and equipment

Goodwill

Intangible assets

Intangible assets under development

Financial assets

Other Financial Assets

Deferred Tax Assets

Income tax assets (net)

Total non-current assets

Current assets

Inventories

Financial assets

Investments

Trade receivables

Cash and cash equivalents

Bank balance other than cash and cash equivalents

Loans

Other financial assets

Other current assets

Total current assets

Total Assets

9.4

0.0

685.7

193.9

21.2

7.2

83.6

1,000.9

14.4

0.0

577.4

212.2

11.2

4.9

71.6

891.7

1,427.4

892.8

112.8

1,313.0

74.6

116.4

0.0

33.0

77.9

3,155.0

4,155.9

134.4

1,540.0

56.7

109.3

0.5

48.9

68.9

2,851.5

3,743.1

Key Financial Performance Indices

Revenue

EBITDA & EBITDA Margin*

Profit After Tax & PAT Margin

Cr.

1,707

1,998

2,003

2,396

3,580

20.7%

18.5%

17.6%

19.0%

20.4%

11.2%

8.8%

8.2%

9.6%

9.8%

353

369

352

455

191

176

165

229

729

349

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

RoCE

RoE

Net Cash & Cash Equivalents^

25.8%

25.7%

18.2%

19.8%

336

18.8%

20.2%

13.9%

14.6%

12.3%

15.2%

269

276

262

FY18

FY19

FY20

FY21

FY22

FY18

FY19

FY20

FY21

FY22

-47 FY18

FY19

FY20

FY21

FY22

* EBITDA is excluding IA & IAUD write-off

^ Total Cash & Cash Equivalents - Debt

On Consolidated Basis

Historical Profit & Loss

Particulars

Revenue from Operations

COGS

Gross Profit

Gross Margin %

Employee Expenses

Other Expenses

EBITDA*

EBITDA Margin %

Forex (Gain)/Loss

Depreciation

Other Income

EBIT

EBIT Margin %

Finance Cost

PBT

Tax Expense

PAT

PAT Margin %

Earnings Per Share (EPS) In Rs.

* EBITDA is excluding IA & IAUD write-off

FY22

3,579.8

2,499.8

1,080.0

30.2%

44.2

336.4

728.6

20.4%

16.5

245.3

28.9

466.5

13.0%

2.2

464.2

115.0

349.3

9.8%

38.71

FY21

2,395.6

1,636.0

759.7

31.7%

37.3

305.5

455.2

19.0%

-19.9

170.4

45.9

312.2

13.0%

2.8

309.5

80.2

229.2

9.6%

25.40

FY20

2,003.0

1,388.8

614.3

30.7%

34.9

282.4

351.7

17.6%

15.1

137.1

42.1

186.8

9.3%

1.9

184.9

20.2

164.7

8.2%

18.25

FY19

1,997.6

1,387.3

610.2

30.5%

33.5

250.1

368.8

18.5%

4.5

99.4

20.6

243.4

12.2%

8.4

235.0

58.7

176.3

8.8%

19.55

Cr.

FY18

1,706.6

1,143.7

562.8

33.0%

33.5

183.9

353.3

20.7%

-8.5

69.9

8.1

292.1

17.1%

4.9

287.2

96.4

190.8

11.2%

21.15

On Consolidated Basis

Balance Sheet – Equity & Liabilities

Equities & Liabilities Shareholder's Funds Equity and Share Capital Other Equity Non-controlling Interest Total Equity

Non-Current Liabilities Borrowings Trade Payables Lease Liabilities Other Financial Liabilities Provisions Deferred Tax Liabilities (net) Total Non-Current Liabilities

Current Liabilities Borrowings Lease Liabilities Trade Payables Other Financial Liabilities Other Current Liabilities Current Tax Liabilities Provisions Total Current Liabilities Total Equity & Liabilities

FY22

90.2 1,822.2 0.3 1,912.8

- 2.4 3.5 1.6 2.3 128.9 138.6

38.0 5.1 1,177.6 324.8 55.4 4.2 86.7 1,691.8 3,743.1

FY21

90.2 1,524.1 0.3 1,614.6

- 2.4 8.4 3.2 3.0 92.9 109.9

67.8 4.5 806.8 149.1 58.0 3.2 50.0 1,139.4 2,863.9

FY20

90.2 1,312.6 0.3 1,403.1

0.1 2.4 - 13.1 2.7 69.3 87.5

0.0 - 686.7 89.7 54.4 1.5 24.4 856.7 2,347.2

FY19

90.2 1,193.7 0.2 1,284.1

0.1 2.9 - 1.4 2.2 91.0 97.6

0.0 - 636.2 104.0 60.7 0.6 20.1 821.7 2,203.3

Cr.

FY18

90.2 1,044.6 0.2 1,135.0

0.1 3.0 - 0.3 2.1 83.1 88.6

169.6 - 633.8 106.2 56.1 24.0 12.9 1,002.6 2,226.2

On Consolidated Basis

Balance Sheet - Assets

ASSETS

Assets

Non-Current Assets

Property, Plant and Equipment

Goodwill

Other Intangible assets

Intangible assets under development

Deferred Tax Assets (net)

Non-Current Tax Assets

Other financial assets

Total Non-Current Assets

Current Assets

Inventories

Investments

Trade Receivables

Cash & Cash equivalents

Other Bank balances

Loans

Other Financial Assets

Other Current Assets

Total Current Assets

Total Assets

FY22

FY21

FY20

FY19

FY18

Cr.

14.4

0.0

577.4

212.2

4.9

71.6

11.2

891.7

892.8

134.4

1,540.0

56.7

109.3

0.5

48.9

68.9

2,851.5

3,743.1

20.9

0.4

523.1

131.0

6.0

73.6

9.4

764.5

525.5

83.0

1,162.6

85.6

175.0

28.1

39.6

2,099.3

2,863.9

27.8

0.4

388.1

161.4

3.9

72.5

11.6

665.7

382.2

115.5

988.4

77.8

75.7

11.3

29.6

13.5

0.4

357.8

219.8

5.5

49.2

8.9

655.2

364.9

211.9

811.4

50.6

73.0

11.9

24.3

10.7

0.4

215.2

359.9

40.0

29.3

7.3

662.9

530.4

22.1

891.9

61.3

39.3

0.0

18.3

1,681.5

2,347.2

1,548.2

2,203.3

1,563.3

2,226.2

On Consolidated Basis

CSR Activities

CSR initiatives taken up by the Company are in the areas of Promoting Education, Healthcare, Eradicating Hunger, Empowerment of Women, Animal Welfare, Promotion of Sports and Rural Development Projects

Promoting Education

Animal Welfare

Medical Aid & Relief

THANK YOU

Company: Sharda Cropchem Limited

Investor Relation Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: L67120MH1995PLC086696

CIN: U74140MH2010PTC204285

Mr. Ashok Vashisht - CFO cfo@shardaintl.com Tel: +91 22 6678 2800

Mr. Deven Dhruva deven.dhruva@sgapl.net Tel: +91 98333 73300

← All Transcripts SHARDACROP Stock Page →

Sharda Cropchem Limited has informed the Exchange about Investor Presentation

Market Movers